Evolving Strategies in the Diagnosis and Treatment of Muscle-Invasive Bladder Cancer – Live

Description

Program Description

---

Click to Go to the Event Registration

This CME/CE live webinar will provide an evidence-based update on muscle-invasive bladder cancer (MIBC), reviewing the clinical spectrum, histopathology, and evolving diagnostic approaches—including mutational profiling, urine testing, and ctDNA. Faculty will also discuss current and emerging treatment strategies, with practical guidance on integrating chemo-immunotherapy, immunotherapy, and antibody-drug conjugates, as well as best practices for recognizing and managing immunotherapy-related toxicities in clinical practice.

Agenda

---

• Summarize the clinical spectrum, histopathology, mutational burden, urine and ctDNA based diagnosis of MIBC – Seth Lerner, MD
• Integrate chemoimmunotherapy, immunotherapy, antibody-drug conjugates, combinations and management of immunotherapy-related toxicities for the treatment of MIBC – Matthew Galsky, MD

Intended Audience

---

This activity is designed to meet the educational needs of US medical oncologists, ex-US medical oncologists, urologists, advanced practice providers (physician assistants and nurse practitioners), and nurses who manage patients with muscle-invasive bladder cancer (MIBC).

Commercial Supporter

---

Supported by an educational grant from Pfizer, Inc. and Astellas Pharma US, Inc.